According to a new report published by Allied Market Research, titled, “Oral Proteins and Peptides Market by Drug Type and Application: Global Opportunity Analysis and Industry Forecast, 2022-2028,” the global oral proteins and peptides market was valued at $643 million in 2016, and is projected to reach $8,233 million by 2023, growing at a CAGR of 11.7% from 2022 to 2028. The linaclotide drug type segment occupied the highest market share of the market in 2016.
𝐋𝐢𝐬𝐭 𝐨𝐟 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 :
The report provides extensive competitive analysis and profiles of key market players, such as Allergan plc, AstraZeneca plc, Biocon Limited, Chiasma, Inc., Proxima Concepts Limited (Diabetology Ltd.), Generex Biotechnology Corp., Novo Nordisk A/S, Synergy Pharmaceuticals Inc., and Tarsa Therapeutics Inc. Other players (profiles not included in the report) in the value chain analysis include Sanofi S.A., F. Hoffmann-La Roche AG, Synthetic Biologics, Inc., Hovione Limited, and Novartis International AG.
𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://www.alliedmarketresearch.com/request-sample/378
𝐊𝐄𝐘 𝐅𝐈𝐍𝐃𝐈𝐍𝐆𝐒 𝐎𝐅 𝐓𝐇𝐄 𝐒𝐓𝐔𝐃𝐘
- The insulin drug type segment is anticipated to grow at the highest CAGR from 2022 to 2028
- The gastric & digestive disorder application segment is anticipated to occupy the largest share in the oral proteins and peptides market
- The diabetes segment is expected to witness the highest growth rate during the forecast period
- The U.S. dominated the oral proteins and peptides market, and is projected to grow at a CAGR of 11.7%
𝐅𝐨𝐫 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲 https://www.alliedmarketresearch.com/purchase-enquiry/378
The major factors that drive the growth of the global oral proteins and peptides market include increase in collaborative efforts between pharmaceutical companies, surge in prevalence of chronic conditions, increase in elderly population, and rise in awareness & preference among populace for oral proteins and peptide-based drugs.
However, high cost associated with drug development and low bioavailability of these drugs impede the market growth. Conversely, increase in novel indications for known oral protein therapeutics, high R&D investment by pharmaceutical companies in oral proteins & peptides drugs, and rise in purchasing power in the emerging markets are anticipated to provide lucrative opportunities for the manufacturers in this industry.
The gastric & digestive disorders application generated the highest revenue in 2016, and is anticipated to continue this trend in the future. This is attributed to the approval and high adoption of oral proteins and peptide drugsLINZESS (Allergan, Inc.) and TRULANCE (Synergy Pharmaceuticals, Inc.). The diabetes application is anticipated to grow at the highest CAGR of 13.4% from 2022 to 2028.
𝗚𝗲𝘁 𝗗𝗲𝘁𝗮𝗶𝗹𝗲𝗱 𝐑𝐞𝐩𝐨𝐫𝐭 https://www.alliedmarketresearch.com/oral-proteins-peptides-market
The U.S. held the highest market share in 2016, owing to high prevalence rate of chronic diseases, rise in adoption of these drugs, and increase in awareness about oral protein and peptide therapeutics. The rest of the world is expected to grow owing to rapid industrialization, increase in disposable income, and upsurge in government initiatives to modernize healthcare infrastructure.
𝐎𝐭𝐡𝐞𝐫 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
5933 NE Win Sivers Drive
205, Portland, OR 97220
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060